AGP Picks
View all

Informing on health and wellness news in Mississippi

Provided by AGP

Mississippi Healthcare Reporter
Got News to Share?
Got News to Share? globe Explore more publications!

Mississippi Healthcare Reporter: Press Releases

Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on Mississippi Healthcare Reporter.

March 2026

Mo Tu We Th Fr Sa Su
1
2 3 4 5 6 7 8
9 10 11 12 13 14 15
16 17 18 19 20 21 22
23 24 25 26 27 28 29
30 31

April 2026

Mo Tu We Th Fr Sa Su
1 2 3 4 5
6 7 8 9 10 11 12
13 14 15 16 17 18 19
20 21 22 23 24 25 26
27 28 29 30

May 2026

Mo Tu We Th Fr Sa Su
1 2 3
4 5 6 7 8 9 10
11 12 13 14 15 16 17
18 19 20 21 22 23 24
25 26 27 28 29 30 31

Press releases published on May 18, 2026

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics
May 18, 2026

FibroBiologics Files Patent Application for Oral Administration of Fibroblast Therapeutics

Indeterminate GlobeNewswire
Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference
May 18, 2026

Fortress Biotech to Participate in A.G.P.’s Annual Virtual Healthcare Conference

Indeterminate GlobeNewswire
Alpha Tau to Participate in May Investor Conferences
May 18, 2026

Alpha Tau to Participate in May Investor Conferences

Indeterminate GlobeNewswire
ORAGENICS PROVIDES INVESTOR UPDATE
May 18, 2026

ORAGENICS PROVIDES INVESTOR UPDATE

Indeterminate GlobeNewswire
Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact
May 18, 2026

Teva Study Finds Only 23% of Younger Adults with Mood Disorders and Tardive Dyskinesia (TD) Symptoms Are Formally Diagnosed with TD Despite Widespread Impact

Indeterminate GlobeNewswire
CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs
May 18, 2026

CytomX Therapeutics Appoints Mamata Gokhale, Ph.D., RAC, as Senior Vice President of Regulatory Affairs

Indeterminate GlobeNewswire
Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference
May 18, 2026

Recludix Pharma to Present at RBC Capital Markets Global Healthcare Conference

Indeterminate GlobeNewswire
Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option
May 18, 2026

Rein Therapeutics Announces Closing of $57.5 Million Underwritten Public Offering, Including Full Exercise of Over-Allotment Option

Indeterminate GlobeNewswire
Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026
May 18, 2026

Alignment Healthcare to Present at the Goldman Sachs 47th Annual Global Healthcare Conference 2026

Indeterminate GlobeNewswire
SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System
May 18, 2026

SpyGlass Pharma Announces New Add-on Category III CPT Code for Its Innovative BIM-IOL System

Indeterminate GlobeNewswire
Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase
May 18, 2026

Reviva to Participate in Fireside Chat at A.G.P.’s Annual Healthcare Company Showcase

Indeterminate GlobeNewswire
BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease
May 18, 2026

BioVie Announces Completion of Phase 2 SUNRISE-PD Trial in Early-Stage Parkinson’s Disease

Indeterminate GlobeNewswire
Syneos Health Wins “Best Mobile App for Patient Engagement” in 2026 MedTech Breakthrough Awards
May 18, 2026

Syneos Health Wins “Best Mobile App for Patient Engagement” in 2026 MedTech Breakthrough Awards

Indeterminate GlobeNewswire
Kyverna Therapeutics Names Greg Martini as Chief Financial Officer
May 18, 2026

Kyverna Therapeutics Names Greg Martini as Chief Financial Officer

Indeterminate GlobeNewswire
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies
May 18, 2026

Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies

Indeterminate GlobeNewswire
Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End
May 18, 2026

Provectus Biopharmaceuticals Reports Oral PV-10 Anti-Tumor Activity in Preclinical Bladder Cancer Study; Long-Term Survivors Show Absence of Gross Bladder Tumor at Study End

Indeterminate GlobeNewswire
Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026
May 18, 2026

Protara Therapeutics to Host Virtual Investor Webinar to Discuss TARA-002 for Lymphatic Malformations on Tuesday, May 19, 2026

Indeterminate GlobeNewswire
Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer
May 18, 2026

Route 92 Medical Announces Appointment of Raj Denhoy as Chief Financial Officer

Indeterminate GlobeNewswire
CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION
May 18, 2026

CATHETER PRECISION REPORTS 200% REVENUE GROWTH AND COMPLETES TRANSFORMATIVE FLYTE ACQUISITION

Indeterminate GlobeNewswire
Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa
May 18, 2026

Krystal Biotech Announces United Kingdom MHRA Approval of VYJUVEK® for the Treatment of Dystrophic Epidermolysis Bullosa

Indeterminate GlobeNewswire
Show More

Share us

on your social networks:
LinkedIn Facebook

Sign up for:

Mississippi Healthcare Reporter

The daily local news briefing you can trust. Every day. Subscribe now.

By signing up, you agree to our Terms & Conditions.